Next Article in Journal
Adenosine Targeting as a New Strategy to Decrease Glioblastoma Aggressiveness
Previous Article in Journal
Connected-SegNets: A Deep Learning Model for Breast Tumor Segmentation from X-ray Images
 
 
Article
Peer-Review Record

Recurrent NOMO1 Gene Deletion Is a Potential Clinical Marker in Early-Onset Colorectal Cancer and Is Involved in the Regulation of Cell Migration

Cancers 2022, 14(16), 4029; https://doi.org/10.3390/cancers14164029
by Jésica Pérez-García 1,2,3,†, Abel Martel-Martel 1,2,4,†, Paula García-Vallés 1,2, Luis A. Corchete 3,5,6, Juan L. García 1,3, Nerea Gestoso-Uzal 1,2, Rosario Vidal-Tocino 1,4, Óscar Blanco 1,7, Lucía Méndez 1,8, Manuel Sánchez-Martín 1,8, Manuel Fuentes 9,10, Ana B. Herrero 1,2,3, Andreana N. Holowatyj 11, José Perea 1 and Rogelio González-Sarmiento 1,2,3,*
Reviewer 1:
Reviewer 2:
Cancers 2022, 14(16), 4029; https://doi.org/10.3390/cancers14164029
Submission received: 13 July 2022 / Revised: 16 August 2022 / Accepted: 19 August 2022 / Published: 20 August 2022

Round 1

Reviewer 1 Report

This is an interesting study in the new area of Molecular tumor biology leading to more research for clinical evaluation.

Author Response

Point 1: This is an interesting study in the new area of Molecular tumor biology leading to more research for clinical evaluation.

Response 1: We thank the Reviewer for this comment.

Author Response File: Author Response.docx

Reviewer 2 Report

Authors has revealed that NOMO1, a gene that is specifically deleted or inactivated in EOCRCs, contributes to cancer cell migration. The manuscript was informative and persuasive. I have few minor comments:

1. Does the title accurately describe the manuscript? The more mechanistic aspect of NOMO1 is described than just a 'clinical marker'. 

2. Can Fig.5 Western blot analysis results be quantified? The upregulation of HMGA1 in HS-5 is clear but that in HCT-116 is not so clear.

Author Response

Authors has revealed that NOMO1, a gene that is specifically deleted or inactivated in EOCRCs, contributes to cancer cell migration. The manuscript was informative and persuasive. I have few minor comments:

Point 1: Does the title accurately describe the manuscript? The more mechanistic aspect of NOMO1 is described than just a 'clinical marker'.

Response 1: We appreciate this suggestion from the Reviewer. The manuscript tittle has been changed to “Recurrent NOMO1 Gene Deletion is a Potential Clinical Marker in Early-Onset Colorectal Cancer and is involved in the regulation of cell migration”.

Point 2: Can Fig.5 Western blot analysis results be quantified? The upregulation of HMGA1 in HS-5 is clear but that in HCT-116 is not so clear.

Response 2: We thank the Reviewer for raising this point. Fig.5 western blot analysis has been quantified and added to the main text as Fig 5.B.

Author Response File: Author Response.docx

Back to TopTop